Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disease burden
DUBLIN and BRIDGEWATER, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted recently published data in the European Journal of Preventive Cardiology showing in a post hoc analysis of the landmark REDUCE-IT study that, among statin-treated participants with elevated triglycerides and known CVD or with diabetes and other risk factors, patients treated with VASCEPA®/VAZKEPA® (icosapent ethyl) (IPE) experienced fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disease burden.i
The analysis evaluated 8,179 participants randomized to receive either IPE 2 g twice daily or placebo and followed for a median of five years and determined if treatment with IPE would decrease the frequency and duration of hospitalizations.
Commenting on the published findings, Deepak L. Bhatt, MD, MPH, MBA, Director of the Mount Sinai Fuster Heart Hospital at the Icahn School of Medicine at Mount Sinai in New York, said, "What stands out most in this analysis is the real-world relevance for patients and their families. Fewer hospitalizations can make a meaningful difference in daily life - allowing people to maintain independence and spend more time at home. These findings extend the benefits of treatment with IPE beyond cardiovascular prevention to potentially reduce the burden of hospitalizations and increase the chances of an individual living without hospitalization."
Lead author Michael Szarek, PhD, Mount Sinai Fuster Heart Hospital at the Icahn School of Medicine at Mount Sinai in New York and University of Colorado Anschutz Medical Campus, Aurora, CO, added: "For patients already managing heart disease or diabetes, every day outside the hospital matters. In this high-risk population, we saw reductions not only in how often individuals were hospitalized, but also in how much time they lost to being in the hospital or from premature death. These patient focused outcomes reinforce that IPE may help people spend more time living their lives and less time receiving acute medical care - a result with great significance for patients, their families, and the healthcare system at large."
Data from REDUCE-IT have consistently shown robust relative and absolute risk reductions in the primary analyses and several sub-group analyses, which led to incorporation of IPE in multiple guidelines and consensus statements globally.ii